Peroxisome proliferator-activated receptor agonists

Current Opinion in Chemical Biology

Volumn 1, Issue 2, 1997, Pages 235-241

  Willson, Timothy M ^a   Wahli, Walter ^b  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CELL RECEPTOR; LIGAND; TRANSCRIPTION FACTOR;

DRUG POTENTIATION; HUMAN; METABOLISM; REVIEW;

ANTILIPEMIC AGENTS; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0031197036     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(97)80015-4     Document Type: Article

References (55)

1. Mangelsdorf DJ, Evans RM: The RXR heterodimers and orphan receptors. Cell 1995, 83:841-850.
2. Green S, Wahli W: Peroxisome proliferator-activated receptors: finding the orphan a home. Mol Cell Endocrinol 1994, 100:149-153.
3. Wahli W, Braissant O, Desvergne B: Peroxisome proliferator activated receptors: transciptional regulators of adipogenesis, lipid metabolism and more. Chem Biol 1995, 2:261-266.
4. Smith SA: Peroxisomal proliferator activated receptors (PPARs). Molecular targets for hypolipidemic agents and insulin sensitizers. Pharmacol Rev Commun 1996, 8:57-64.
5. McDonnell DP, Vegeto E, Gleeson MAG: Nuclear hormone receptors as targets for new drug discovery. Bio/Technology 1993, 11:1256-1261.
6. Soontjens CD, Rafter JJ, Gustafsson JA: Ligands for orphan receptors? J Endocrinol 1996, 150:S241-S257.
7. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1995, 270:12953-12956.
8. Yu K, Bayona W, Kallne CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA: Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995, 270:23975-23983.
9. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, Thaller C: 9-Cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992, 68:397-406.
10. Levin AA, Sturzenbecker LJ, Kazmer S, Bosakowski T, Huselton C, Allenby G, Speck J, Kratzeisen C, Rosenberger M, Lovey A, Grippo JF: 9-Cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRα. Nature 1992, 355:359-361.
11. O'Malley BW, Conneely OM: Orphan receptors: in search of a unifying hypothesis for activation. Mol Endocrinol 1992, 6:1359-1361.
12. Dowell P, Peterson VJ, Zabriskie TM, Leid M: Ligand-induced peroxisome proliferator-activated receptor a conformational change. J Biol Chem 1997, 272:2013-2020.
13. Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W: Fatty acids, eicosanoids and hypolipedemic agents identified as ligands of peroxisome proliferator-activated receptors by CARLA. Mol Endocrinol 1997, 11:779-791. A novel in vitro ligand detection assay is described that measured the ligand-dependent association of SRC1 with xPPARs. Using this assay, the authors identified a series of synthetic and naturally occurring PPAR ligands.
14. Forman BM, Chen J, Evans RM: Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for PPARα and PPARγ. Proc Natl Acad Sci USA 1997, 94:4312-4317 The authors developed a novel in vitro assay that measured the ligand-dependent association of mPPARs with DNA. Using this assay, a series of synthetic and naturally occurring PPAR ligands was identified.
15. 3H]-GW 2331. In competition binding assays, a series of synthetic and naturally occurring PPAR ligands was identified for xPPARα and xPPARγ.
16. Isseman I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347:645-650.
17. Mukherjee R, Jow L, Noonan D, McDonnell DP: Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different reponsiveness to PPAR activators. J Steroid Biochem Mol Biol 1994, 51:157-166.
18. Rangwala SM, Shamina M, O'Brien ML, Tortorella V, Longo A, Loiodice F, Noonan DJ, Feller DR: Stereoeselective effects of chiral clofibric acid analogs on rat peroxisome proliferator-activated receptor α (rPPARα) activation and peroxisomal fatty acid β-oxidation. Chirality 1997, 9:37-47.
19. Pineau T, Hudgins WR, Liu L, Chen L, Sher T, Gonzalez FJ, Samit D: Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharmacol 1996, 52:659-667.
20. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the anti-hyperglycemic activity of thiazolidinediones. J Med Chem 1996, 39:665-668. The authors of this paper recall the history of the development of thiazolidinedione antidiabetic agents. A strong correlation between mPPARγ activity and in vivo antidiabetic activity in mice was demonstrated; providing pharmacological evidence that PPARγ was the molecular target for the antidiabetic activity of these drugs.
21. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995, 83:803-812.
22. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD: Thiazolidinediones produce a conformational change in peroxisome proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996, 137:4189-4195.
23. Schmidt A, Endo N, Rutledge SJ, Voget R, Shinar D, Rodan GA: Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol 1992, 1992:1634-1641.
24. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997, 272:3406-3410.
25. Eacho PI, Foxworthy PS, Lawrence JW, Herron DK, Noonan DJ: Common structural requirements for peroxisome proliferation by tetrazole and carboxylic acid-containing compounds. Ann NY Acad Sci 1996, 804:387-402.
26. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 1994, 91:7355-7359.
27. Boie Y, Mohammed A, Rushmore TH, Kennedy BP: Enantioselective activation of the peroxisome proliferator-activated receptor. J Biol Chem 1993, 268:5530-5534.
28. Gösttlicher M, Widmark E, Li Q, Gustafsson JA: Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 1992, 89:4653-4657.
29. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W: Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 1993, 90:2160-2164.
30. Amri EZ, Bonino F, Ailhaud G, Abumrad NA, Grimaldi PA: Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors. J Biol Chem 1995, 270:2367-2371.
31. Schmidt A, Vogel RL, Witherup KM, Rutledge SJ, Pitzenberger SM, Adam M, Rodan G: Identification of fatty acid methyl esters as naturally occurring transcriptional regulators of the members of the peroxisome proliferator-activated receptor family. Lipids 1996, 31:1115-1124.
32. Banner CD, Gsttlicher M, Widmark J, Sjovall J, Rafter JJ, Gustafsson JA: A systematic analytical chemistry/cell assay approach to isolate activators of orphan nuclear receptors from biological extracts: characterization of peroxisome proliferator-activators in plasma. J Lipid Res 1993, 34:1583-1591.
33. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995, 83:813-819.
34. 4 had a longer duration in PPARa KO mice. The authors propose the hypothesis that activation of PPARa regulates the catabolism of proinflammatory eicosanoids.
35. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM: Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992, 358:771-774.
36. Gearing KL, Göttlicher M, Teboul M, Widmark E, Gustafsson JA: Interaction of the peroxisome-proliferator-activated receptor and retinoid x receptor. Proc Natl Acad Sci USA 1993, 90:1440-1444.
37. Mukherjee R, Davies PJA, Crombie DL, Bischoff ED, Cesarie RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nazdan AM et al.: Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997, 386:407-410. The authors describe the in vivo antidiabetic activity of the RXR-selective agonists LG 1069 and LG 100268. Data generated with cell-based assays suggested that antidiabetic activity resulted from activation of PPARγ-RXR heterodimers.
38. Schulman IG, Li C, Schwabe JWR, Evans RM: The phantom ligand effect: allosteric control of transcription by the retinoid X receptor. Genes Dev 1997, 11:299-308.
39. Canan Koch SS, Dardashti LJ, Hebert JJ, White SK, Croston GEF, Flatten KS, Heymann RA, Nazdan AM: Identification of the first retinoid X receptor homodimer antagonist J Med Chem 1996, 39:3229-3234. The authors describe the identification of LG 100754, a novel RXR-selective that was an antagonist of RXR homodimers.
40. Lala D, Mukherjee R, Schuiman IG, Canan Koch SS, Dardashti U, Nazdan AM, Croston GE, Evans RM, Heymann RA: Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature 1996, 383:450-453. The authors describe the functional selectivity of the RXR-selective retinoid LG 100754; the retinoid was an agonist of PPAR-RXR heterodimers but an antagonist of RXR homodimers.
41. Mukherjee R, Jow L, Croston GE, Paterniti JR: Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997, 272:8071-8076.
42. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, β, and -γ in the adult rat Endocrinology 1996, 137:354-366. The authors present a comprehensive study of PPAR tissue distribution in the rat by in situ hybridization.
43. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA: Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994, 135:798-800.
44. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM: mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994, 8:1224-1234.
45. Jones PS, Savory R, Barratt P, Bell AR, Gray TJB, Jenkins NA, Gilbert DJ, Copeland NG, Bell DR: Chromosomal localization, inducibility, tissue-specific expression and strain differences in three murine peroxisome proliferator-activated receptor genes. Eur J Biochem 1995, 233:219-226.
46. Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer SD: Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expression 1995, 4:281-299.
47. Lemberger T, Saladin R, Vazquez M, Assimacopoulos F, Staels B, Desvergne B, Wahli W, Auwerx J: Expression of the peroxisome proliferator-activated receptor α gene is stimulated by stress and follows a diurnal rhythm. J Biol Chem 1996, 271:1764-1769. The authors showed that, in rats, PPARα expression levels in the liver respond to physiological changes in circulating glucocorticoid levels.
48. Lemberger T, Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 1996, 12:335-363.
49. Lee SST, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ: Targeted disruption of the a isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995, 15:3012-3022.
50. Lee SST, Gonzalez FJ: Targeted disruption of the peroxisome proliferator-activated receptor α gene, PPAR α. Ann NY Acad Sci 1996 804:524-529.
51. Tontonoz P, Hu E, Spiegelman BM: Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor y. Curr Opin Genet Dev 1995, 5:571-576.
52. Tontonoz P, Hu E, Speigelman BM: Stimulation of adipogenesis on fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994, 79:1147-1156.
53. Brun RP, Tontonoz P, Forman BM, Ellis R, Chen J, Evans RM, Spiegelman BM: Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev 1996, 10:974-984. The authors ectopically expressed each of the PPAR subtypes in fibroblast cells. Only the cells expressing PPARγ showed a strong induction of the adipocyte phenotype when treated with a PPAR activator.
54. Tai TAC, Jennermann C, Brown KK, Oliver BB, MacGinnitie MA, Wilkison WO, Brown HR, Lehmann JM, Kliewer AS, Graves RA: Activation of the nuclear receptor peroxisome proliferator-activated receptor γ promotes brown adipocyte differentiation. J Biol Chem 1996, 271:29909-29914. The authors report that treatment of rats with the thiazolinedione BRL 49653 resulted in an increase in the mass of brown fat and increased expression of the uncoupling protein in this tissue. Cell culture studies showed that BRL 49653 regulated the expression of the uncoupling protein through activation of PPARγ.
55. Silva JE, Rabelo R: Regulation of the uncoupling protein gene expression. Eur J Endocrinol 1996, 136:251-264.